



FORESEE BIOSYSTEMS

Giulia Bruno, PhD
Chief Technology Officer
giulia.bruno@foreseebiosystems.com


ABOUT OUR COMPANY

Foresee Biosystems operates from Genoa, Italy, since 2021. It was established by researchers of the Italian Institute of Technology (IIT).


Foresee is a high-tech company developing and selling products and services in the field **of in vitro cell screenings.**



COMPANY HISTORY



2021



2022




2023

The unique laser technology of Foresee was developed at the Italian Institute of Technology (IIT) in Genova, Italy. IIT patented the technology in 2018.



Foresee acquired the exclusive rights of the patent in 2021, and developed its first product, IntraCell, from 2021 to 2023.

THE TECHNOLOGY

Intracellular Recording





Patch clamp




Measures membrane potential inside the cell
Full action potential + subthreshold signals
High amplitude (60–100 mV)
Single-cell precision

Extracellular Recording




Multielectrode array



Measures voltage outside the cell
Spikes only (no subthreshold)
Low amplitude (10–500 μ V)
Multi-site, scalable recordings

THE TECHNOLOGY


- Optoporation -



patch-clamp-like accuracy

high-throughput measurements

- An ultrafast laser creates temporary nanopores in the cell membrane
- The pore reseals spontaneously, preserving cell viability
- Enables electrical access to the cell interior
- Enables high-throughput measurements with patch-clamp-like accuracy
- Allows intracellular recordings in tissues, not only isolated cells
- Easily combined with other techniques (optical imaging, stimulation, pharmacology)



We developed the first line of laser-based products for pharmacology and low-invasiveness in vitro studies. Thanks to our patented technology, we can record action potentials in human cardiac cells, enabling long-term cardiotoxicity assessment.


SOFTWARE :FBAlps

INSTRUMENT: IntraCell



THE PROBLEMs WE SOLVE



Cardiovascular diseases → **1st cause of death**



Excitation-contraction coupling (ECC) **poorly investigated due to the lack of technologies.**



Preclinical in vitro therapeutic testing

Advanced human models

→ **NO suitable technologies**



Increasing trend of drug toxic effects

Cardiotoxicity



Slow drug development



High costs

1



Cardiovascular diseases (CVDs) are the **first** cause of death worldwide. Despite new technologies being developed in the past years there are still unresolved issues, such as the comprehensive study of the excitation contraction coupling.

2




Biologists have developed advanced human in vitro models that can recapitulate faithfully the human body (3D organoids), but current technologies are not designed to study those advanced human models.

3




Cardiotoxicity plays a critical role as it is one of the main causes for rejection of new molecular entities.



CARDIAC ORGANOIDS



CARDIAC CELLS



NEURONAL CELLS

MEET OUR TEAM MEMBERS

ELECTRONICS ENGINEER

Stefanos Ioakeimidis


PhD in electrical engineering



CEO

Michele Dipalo

PhD in electrical engineering



SOFTWARE ENGINEER

Carolina Scandellari

MD Biomedical engineering



MECHANICAL ENGINEER

Leonardo Toccafondi

MD Mechanical engineering

SOFTWARE ENGINEER

Alice Godino

MD Biomedical engineering

CTO

Giulia Bruno

PhD Biomedical engineering and Robotics



Our **board of directors** includes recognized scientists and successful entrepreneurs with a strong track record in business development



Director
Karl-Heinz Boven



Director
Andreas Moeller

25 anni di esperienza nello stesso mercato di Foresee Biosystems.
Co-founder di **Multi Channel System MCS GmbH**
Ex-direttori di MCS Holding GmbH





THANK YOU

VISIT US



+39-340-1396829



Michele.dipalo@foreseebiosystems.com